CD274 and non-small cell lung carcinoma: In 111 NSCLC patients with MET exon 14 skipping mutations, Sabari et al. found a higher PD-L1 expression than expected from the above-mentioned studies, with 22%, and 41% having PD-L1 expression of 1–49%, and ≥ 50%, respectively [80].